When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

被引:147
|
作者
Cheng, Gang [1 ,2 ]
Torigian, Drew A. [2 ]
Zhuang, Hongming [3 ]
Alavi, Abass [2 ]
机构
[1] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA
[2] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA
关键词
FDG; PET/CT; Dual time-point imaging; Cancer; Diagnosis; CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; PHASE F-18-FDG PET; LYMPH-NODE METASTASES; TUBERCULOSIS-ENDEMIC COUNTRY; SOLITARY PULMONARY NODULES; BREAST-CANCER; GALLBLADDER CARCINOMA; HEPATIC METASTASES; GLUCOSE-METABOLISM;
D O I
10.1007/s00259-013-2343-9
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
FDG PET and PET/CT are now widely used in oncological imaging for tumor characterization, staging, restaging, and response evaluation. However, numerous benign etiologies may cause increased FDG uptake indistinguishable from that of malignancy. Multiple studies have shown that dual time-point imaging (DTPI) of FDG PET may be helpful in differentiating malignancy from benign processes. However, exceptions exist, and some studies have demonstrated significant overlap of FDG uptake patterns between benign and malignant lesions on delayed time-point images. In this review, we summarize our experience and opinions on the value of DTPI and delayed time-point imaging in oncology, with a review of the relevant literature. We believe that the major value of DTPI and delayed time-point imaging is the increased sensitivity due to continued clearance of background activity and continued FDG accumulation in malignant lesions, if the same diagnostic criteria (as in the initial standard single time-point imaging) are used. The specificity of DTPI and delayed time-point imaging depends on multiple factors, including the prevalence of malignancies, the patient population, and the cut-off values (either SUV or retention index) used to define a malignancy. Thus, DTPI and delayed time-point imaging would be more useful if performed for evaluation of lesions in regions with significant background activity clearance over time (such as the liver, the spleen, the mediastinum), and if used in the evaluation of the extent of tumor involvement rather than in the characterization of the nature of any specific lesion. Acute infectious and non-infectious inflammatory lesions remain as the major culprit for diminished diagnostic performance of these approaches (especially in tuberculosis-endemic regions). Tumor heterogeneity may also contribute to inconsistent performance of DTPI. The authors believe that selective use of DTPI and delayed time-point imaging will improve diagnostic accuracy and interpretation confidence in FDG PET imaging.
引用
收藏
页码:779 / 787
页数:9
相关论文
共 50 条
  • [1] When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?
    Gang Cheng
    Drew A. Torigian
    Hongming Zhuang
    Abass Alavi
    European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40 : 779 - 787
  • [2] Dual time-point imaging of lymphoma adenopathy using total-body FDG PET/CT
    Shrestha, Bimash
    Singh, Shashi
    Motamedi, Niloofaralsadat
    Werner, Thomas
    Nardo, Lorenzo
    Abdelhafez, Yasser
    Alavi, Abass
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [3] Comparison of Single Time-Point [111-In] Pentetreotide SPECT/CT With Dual Time-Point Imaging of Neuroendocrine Tumors
    Wong, Ka Kit
    Wynn, Elizabeth A.
    Myles, Jamie
    Ackermann, Robert J.
    Frey, Kirk A.
    Avram, Anca M.
    CLINICAL NUCLEAR MEDICINE, 2011, 36 (01) : 25 - 31
  • [4] Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results
    Sofie Bæk Christlieb
    Casper Nørgaard Strandholdt
    Birgitte Brinkmann Olsen
    Karen Juul Mylam
    Thomas Stauffer Larsen
    Anne Lerberg Nielsen
    Max Rohde
    Oke Gerke
    Karen Ege Olsen
    Michael Boe Møller
    Bjarne Winther Kristensen
    Niels Abildgaard
    Abass Alavi
    Poul Flemming Høilund-Carlsen
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1824 - 1836
  • [5] Evaluation of dual time-point fluorodeoxyglucose PET/computed tomography imaging in gastric cancer
    Tasdemir, Bekir
    Guzel, Yunus
    Komek, Halil
    Can, Canan
    NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (12) : 1322 - 1327
  • [6] Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results
    Christlieb, Sofie Baek
    Strandholdt, Casper Norgaard
    Olsen, Birgitte Brinkmann
    Mylam, Karen Juul
    Larsen, Thomas Stauffer
    Nielsen, Anne Lerberg
    Rohde, Max
    Gerke, Oke
    Olsen, Karen Ege
    Moller, Michael Boe
    Kristensen, Bjarne Winther
    Abildgaard, Niels
    Alavi, Abass
    Hoilund-Carlsen, Poul Flemming
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (10) : 1824 - 1836
  • [7] Delayed time-point 18F-FDG PET CT imaging enhances assessment of atherosclerotic plaque inflammation
    Blomberg, Bjoern A.
    Akers, Scott R.
    Saboury, Babak
    Mehta, Nehal N.
    Cheng, Gang
    Torigian, Drew A.
    Lim, Esther
    Del Bello, Catherine
    Werner, Thomas J.
    Alavi, Abass
    NUCLEAR MEDICINE COMMUNICATIONS, 2013, 34 (09) : 860 - 867
  • [8] TIME-POINT SETS AND METER
    JOHNSON, WM
    PERSPECTIVES OF NEW MUSIC, 1984, 23 (01) : 278 - 293
  • [9] Choline PET/CT for the diagnosis of parathyroid adenoma: is there any role for a dual time-point imaging?
    Bastidas, J.
    Belaustegui, L. Garcia
    Bronte, A.
    Betech, V.
    De Andres, H. Casal
    Rosales, J. J.
    Minguez, F.
    Garcia Goni, M.
    Salvador, P.
    Arbizu, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S135 - S135
  • [10] Interobserver agreement with dual time-point FDG-PET/CT in suspected recurrent breast cancer
    Falch, K.
    Baun, C.
    Vestergaard, S.
    Gerke, O.
    Hoilund-Carlsen, P. F.
    Hildebrandt, M. G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S623 - S623